Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$27.51 USD
+0.49 (1.81%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $28.00 +0.49 (1.78%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 27.51 +0.49(1.81%)
Will NTLA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?
Other News for NTLA
Intellia opts out of hemophilia pact with Regeneron
Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals
Hot Stocks: The 3 Best Opportunities for Investing in BiotechÂ
3 Stocks That Could Be the Next Big Thing in Gene Editing
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy